ES3021189T3 - Treatment of angelman syndrome with gaboxadol - Google Patents

Treatment of angelman syndrome with gaboxadol Download PDF

Info

Publication number
ES3021189T3
ES3021189T3 ES16828266T ES16828266T ES3021189T3 ES 3021189 T3 ES3021189 T3 ES 3021189T3 ES 16828266 T ES16828266 T ES 16828266T ES 16828266 T ES16828266 T ES 16828266T ES 3021189 T3 ES3021189 T3 ES 3021189T3
Authority
ES
Spain
Prior art keywords
gaboxadol
patient
hours
administration
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16828266T
Other languages
English (en)
Spanish (es)
Inventor
Matthew During
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Application granted granted Critical
Publication of ES3021189T3 publication Critical patent/ES3021189T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES16828266T 2015-07-17 2016-07-14 Treatment of angelman syndrome with gaboxadol Active ES3021189T3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562193717P 2015-07-17 2015-07-17
US201562207595P 2015-08-20 2015-08-20
US201662332567P 2016-05-06 2016-05-06
US201662346763P 2016-06-07 2016-06-07
PCT/US2016/042238 WO2017015049A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol

Publications (1)

Publication Number Publication Date
ES3021189T3 true ES3021189T3 (en) 2025-05-26

Family

ID=57774846

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16828266T Active ES3021189T3 (en) 2015-07-17 2016-07-14 Treatment of angelman syndrome with gaboxadol

Country Status (17)

Country Link
US (8) US20170014393A1 (enExample)
EP (2) EP4541420A3 (enExample)
JP (3) JP2018520189A (enExample)
KR (2) KR20180031721A (enExample)
CN (2) CN108024997A (enExample)
AU (2) AU2016295138B2 (enExample)
BR (1) BR112018000933A2 (enExample)
CA (1) CA2992734A1 (enExample)
CL (1) CL2018000142A1 (enExample)
CO (1) CO2018000375A2 (enExample)
ES (1) ES3021189T3 (enExample)
HK (1) HK1250951A1 (enExample)
IL (2) IL305342B2 (enExample)
MX (2) MX391708B (enExample)
PE (2) PE20190338A1 (enExample)
TW (2) TWI819995B (enExample)
WO (1) WO2017015049A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3795156A1 (en) * 2014-06-06 2021-03-24 Ovid Therapeutics, Inc. Pharmaceutical composition for treating angelman syndrome
CN108024997A (zh) 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
EP3528807A4 (en) * 2016-11-22 2020-06-17 Ovid Therapeutics Inc METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
US20200268711A1 (en) * 2017-11-14 2020-08-27 Sk Biopharmaceuticals Co., Ltd. Use Of Carbamate Compound For Reducing Or Treating Developmental Disorders Including Fragile X Syndrome, Angelman Syndrome Or Rett Syndrome
KR20210040358A (ko) * 2018-06-14 2021-04-13 오비드 테라퓨틱스 인크. 안젤만 증후군의 치료에서 mir-92a 또는 mir-145의 사용
CN112888437A (zh) * 2018-08-22 2021-06-01 奥维德医疗公司 加波沙朵在治疗胃肠道紊乱和哮喘中的用途
EP3833351A4 (en) * 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS
CN114072154B (zh) * 2018-11-21 2024-03-08 塞迪戈Abc有限责任公司 用于治疗精神障碍的加波沙朵和锂的组合物
KR20210110585A (ko) 2018-11-21 2021-09-08 썰테고 테라퓨틱스 아이엔씨. 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
MX2021007224A (es) 2018-12-17 2021-09-23 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
JP7749169B2 (ja) * 2019-06-07 2025-10-06 クヴァトリス セラピューティクス， インコーポレイテッド 中枢神経系障害を処置するための組成物および方法
EP3982937A4 (en) * 2019-07-15 2022-08-10 Ovid Therapeutics Inc. PHARMACEUTICAL FORMULATIONS WITH GABOXADOL FOR THERAPEUTIC TREATMENT
US11364228B2 (en) 2019-12-18 2022-06-21 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
AU2002227052A1 (en) * 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
MXPA03010596A (es) 2001-05-21 2004-03-09 Lundbeck & Co As H Preparaciones granuladas de gaboxadol.
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
EP1641456B1 (en) 2003-06-25 2010-03-03 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US20070032553A1 (en) 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
US20050215521A1 (en) 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
ZA200607427B (en) * 2004-04-02 2009-02-25 Lundbeck & Co As H Treatment of impaired respiratory function with gaboxadol
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
DE102005020882A1 (de) 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
EP2314289A1 (en) * 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
DK2083811T3 (en) * 2006-11-22 2017-01-30 Clinical Res Ass Llc PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
US20090269795A1 (en) 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090048288A1 (en) 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
CN102137667A (zh) * 2008-09-01 2011-07-27 H.隆德贝克有限公司 包含加波沙朵和patl或oat抑制剂的药物组合物
US20100286762A1 (en) 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
CN102147667A (zh) 2010-02-08 2011-08-10 深圳富泰宏精密工业有限公司 触控笔
CN107050456B (zh) 2010-09-28 2022-08-12 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
US20130309306A1 (en) 2010-12-01 2013-11-21 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
US9480695B2 (en) 2011-09-29 2016-11-01 The University Of Tokyo Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder
US20140371210A1 (en) 2011-10-13 2014-12-18 Jaleva Pharmaceuticals, Llc Methods and compositions for rapid transbuccal delivery of active agents
US20150313915A1 (en) * 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
US20150313913A1 (en) 2013-02-05 2015-11-05 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
EP3795156A1 (en) 2014-06-06 2021-03-24 Ovid Therapeutics, Inc. Pharmaceutical composition for treating angelman syndrome
EP3154979B1 (en) 2014-06-12 2018-03-07 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity.
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
CN108024997A (zh) 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
AU2016304737B2 (en) 2015-08-11 2021-03-11 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
EP3364993B1 (en) 2015-10-22 2022-11-09 Cavion, Inc. Methods for treating angelman syndrome
CA3025473A1 (en) 2016-05-26 2017-11-30 Ovid Therapeutics Inc. Methods of treating behavioral syndromes using pipradrol
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
EP3528807A4 (en) 2016-11-22 2020-06-17 Ovid Therapeutics Inc METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus

Also Published As

Publication number Publication date
US20210030727A1 (en) 2021-02-04
KR20240160666A (ko) 2024-11-11
US20190255027A1 (en) 2019-08-22
EP3324961B1 (en) 2025-03-19
US11096929B2 (en) 2021-08-24
MX391708B (es) 2025-03-21
EP4541420A2 (en) 2025-04-23
IL256912B2 (en) 2024-01-01
JP2018520189A (ja) 2018-07-26
JP2021130687A (ja) 2021-09-09
US20190321342A1 (en) 2019-10-24
HK1250951A1 (zh) 2019-01-18
TW201707700A (zh) 2017-03-01
KR20180031721A (ko) 2018-03-28
US12465597B2 (en) 2025-11-11
IL305342B2 (en) 2026-06-01
CL2018000142A1 (es) 2018-07-13
AU2021250862A1 (en) 2021-11-04
US20170014393A1 (en) 2017-01-19
AU2016295138A1 (en) 2018-02-08
TW202325293A (zh) 2023-07-01
US20230071127A1 (en) 2023-03-09
MX2018000745A (es) 2018-08-15
EP4541420A3 (en) 2025-06-25
IL256912B1 (en) 2023-09-01
EP3324961A4 (en) 2019-03-13
EP3324961A1 (en) 2018-05-30
AU2016295138B2 (en) 2021-11-04
BR112018000933A2 (en) 2018-09-04
JP2023103375A (ja) 2023-07-26
PE20190338A1 (es) 2019-03-07
CO2018000375A2 (es) 2018-04-19
TWI819995B (zh) 2023-11-01
US20180098974A1 (en) 2018-04-12
AU2021250862B2 (en) 2023-11-09
PE20230735A1 (es) 2023-05-03
IL305342A (en) 2023-10-01
WO2017015049A1 (en) 2017-01-26
MX2022004734A (es) 2022-05-13
IL256912A (en) 2018-03-29
US20190117632A1 (en) 2019-04-25
IL305342B1 (en) 2026-02-01
CN108024997A (zh) 2018-05-11
CN116531370A (zh) 2023-08-04
US20180338960A1 (en) 2018-11-29
CA2992734A1 (en) 2017-01-26
EP3324961C0 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
US12465597B2 (en) Methods of treating developmental disorders with gaboxadol
US10426746B2 (en) Methods of treating developmental disorders with biguanides
ES2367868T3 (es) Uso de memantina (namenda) para tratar el autismo, la compulsividad y la impulsividad.
KR20230018384A (ko) T-형 칼슘 채널 조정제의 사용 방법
US20190328719A1 (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine
JP2016074728A (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
ES3004543T3 (en) Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
HK40097170A (zh) 用加波沙朵治疗发育障碍的方法